Proprioception and Sensorimotor Control in Hereditary Sensory and Autonomic Neuropathy

NCT ID: NCT02876939

Last Updated: 2020-09-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2019-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project comprises three sets of physiological studies - testing eight specific hypotheses - that will contribute new knowledge on proprioception and motor control in a genetic disorder that affects specific components of the sensory nervous system.

I: To investigate the neurophysiological basis for disturbed motor control in Hereditary sensory and autonomic neuropathy (HSAN) III II: To investigate the effects of enhancing cutaneous feedback on motor control in HSAN III III: To investigate the cortical representation of proprioceptive inputs in HSAN III

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

HSAN III patients (n=15) and healthy control subjects (n=15) will lay supine on an MRI bed and a tungsten microelectrode inserted percutaneously into a muscle or cutaneous fascicle of the right common peroneal nerve at the fibular head, according to standard techniques employed by Prof Macefield. Neural activity will be acquired, RMS-processed (200 ms) and analysed on computer. The subject's head will be tightly enclosed in a standard clinical 32-channel SENSE head coil and headphones will be provided to minimize noise and to allow communication with the subject. The subject will be placed in the bore of a 3T whole-body scanner for 60-90 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atunomic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HSAN III

Group Type EXPERIMENTAL

kinesiology tape around the hip, knee and ankle joints

Intervention Type OTHER

We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

No kinesiology tape around the hip, knee and ankle joints

Intervention Type OTHER

Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

Control Subjects

Group Type ACTIVE_COMPARATOR

kinesiology tape around the hip, knee and ankle joints

Intervention Type OTHER

We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

No kinesiology tape around the hip, knee and ankle joints

Intervention Type OTHER

Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

kinesiology tape around the hip, knee and ankle joints

We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

Intervention Type OTHER

No kinesiology tape around the hip, knee and ankle joints

Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed genetic diagnosis of HSAN III will be recruited from the Dysautonomia Center at NYU

Exclusion Criteria

* homeless
* active drug or alcohol dependence
* evidence of neurological disorder or diabetes
* exposure to neurotoxic drugs that in the investigator's opinion may compromise results
* Pregnant women
Minimum Eligible Age

16 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Horacio Kaufmann, MD

Role: PRINCIPAL_INVESTIGATOR

New York University Medical School

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York University School of Medicine

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16-00530

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mirroring a Movement
NCT00123448 COMPLETED